The proposed amendments include coverage for cellular therapies which include cellular immunotherapies, chimeric antigen receptor (CAR) T cells, cancer vaccines, and other types of autologous and allogeneic cells for certain therapeutic indications. The language mirrors that of the Food and Drug Administration’s language for approved cellular therapy. New language adds to the specific conditions for which the use of cellular therapies is necessary. The amendments also adjust the conditions in sections one through three to add or move conditions to the proper section.